My four favorite biotech stocks are compelling investments that have skyrocketed in the last five years — and even better, are expected to again outperform the S&P 500 in the next several years.
I wrote about them some five years ago as “the fours Cs” – my four favorite biotechs, only one being a true biotech. At that time, the companies – Cerus (CERS), Curis (CRIS), Compugen (CGEN) and Cepheid (CPHD) were in different stages of development and faced vastly different markets.
The common denominator, besides Wall Street not understanding them, was core technology that was extensive once proven to the world. A secondary driving factor for three of the companies – CERS, CGEN and CPHD – is cost; their systems can radically reduce costs.
These four stocks still have tremendous growth potential – even after trouncing the moves in the S&P 500. How much have they beaten the S&P, which is up 73% over the past five years?
- Cerus: Up 242%
- Curis: Up 562%
- Compugen: Up 637%
- Cepheid: Up 271%
What do these outfits do and why do I like them?